MRVINasdaqPharmaceutical PreparationsFiscal year ends December 31
MARAVAI LIFESCIENCES HOLDINGS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$6.99+0.20 (+2.95%)
Close on Oct 19, 2026
- Market cap
- $1.03B
- P/E (TTM)
- –
- Dividend yield
- –
MARAVAI LIFESCIENCES HOLDINGS, INC. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| TriLink | $119.79M | $196.35M | $224.77M | – | – | – | – | 64.5% | -39.0% |
| Cygnus | $65.96M | $62.84M | $64.18M | – | – | – | – | 35.5% | +5.0% |
| Cygnus | – | $62.84M | $64.18M | $69.93M | $68.42M | $54.90M | $44.42M | – | – |
| Protein Detection | – | – | $0 | $0 | $18.96M | $22.88M | $26.12M | – | – |
| TriLink | – | $196.35M | $224.77M | $813.07M | $711.86M | $206.32M | $72.60M | – | – |
By product or service
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| North America | $112.38M | $127.09M | $141.06M | $339.47M | $317.07M | $150.35M | $84.03M | 60.5% | -11.6% |
| United States | $110.90M | $123.70M | $137.90M | – | – | – | – | 59.7% | -10.3% |
| Asia Pacific | $41.47M | $89.38M | $97.44M | $109.79M | $83.65M | $43.17M | $23.59M | 22.3% | -53.6% |
| Europe, the Middle East and Africa | $30.92M | $42.06M | $49.92M | $432.93M | $397.67M | $90.11M | $34.88M | 16.6% | -26.5% |
| Latin and Central America | $971.00K | $662.00K | $527.00K | $808.00K | $842.00K | $474.00K | $642.00K | 0.5% | +46.7% |
From the segment and revenue-disaggregation notes of Maravai Lifesciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.